

JOSH GREEN, M.D.
GOVERNOR
KE KIA'ĀINA



GOV. MSG. NO. 1207

EXECUTIVE CHAMBERS
KE KE'ENA O KE KIA'ĀINA

May 29, 2025

The Honorable Ronald D. Kouchi
President of the Senate,
and Members of the Senate
Thirty-Third State Legislature
State Capitol, Room 409
Honolulu, Hawai'i 96813

The Honorable Nadine Nakamura
Speaker, and Members of the
House of Representatives
Thirty-Third State Legislature
State Capitol, Room 431
Honolulu, Hawai'i 96813

Aloha President Kouchi, Speaker Nakamura, and Members of the Legislature:

This is to inform you that on May 29, 2025, the following bill was signed into law:

S.B. NO. 1452, S.D. 1,
H.D. 2, C.D. 1

RELATING TO THE UNIFORM CONTROLLED
SUBSTANCE ACT.
ACT 107

Mahalo,

A handwritten signature in black ink that reads "Josh Green M.D.".

Josh Green, M.D.
Governor, State of Hawai'i

on MAY 29 2025

THE SENATE
THIRTY-THIRD LEGISLATURE, 2025
STATE OF HAWAII

ACT 107
S.B. NO. 1452
S.D. 1
H.D. 2
C.D. 1

A BILL FOR AN ACT

RELATING TO THE UNIFORM CONTROLLED SUBSTANCE ACT.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

1 SECTION 1. Section 329-14, Hawaii Revised Statutes, is
2 amended as follows:

3 1. By amending subsection (b) to read:

4 "(b) ~~[Any]~~ Opiates. Unless specifically excepted or
5 unless listed in another schedule, any of the following opiates,
6 including their isomers, esters, ethers, salts, and salts of
7 isomers, esters, and ethers, ~~[unless specifically excepted,]~~
8 whenever the existence of these isomers, esters, ethers, and
9 salts is possible within the specific chemical designation:

10 (1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-
11 phenethyl)-4-piperidinyl]-N-phenylacetamide);

12 (2) Acetylmethadol;

13 (3) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
14 phenylacetamide), its optical, positional, and
15 geometric isomers, salts, and salts of isomers;

16 (4) Acryl fentanyl [N-(1-phenethylpiperidin-4-yl)-N-
17 phenylacrylamide] (Other name: acryloylfentanyl);



- 1 (5) AH-7921 (3,4-dichloro-N-[(1-
2 dimethylamino)cyclohexylmethyl]benzamide);
- 3 (6) Allylprodine;
- 4 (7) Alphacetylmethadol (except levo-alphacetylmethadol,
5 levomethadyl acetate, or LAAM);
- 6 (8) Alphameprodine;
- 7 (9) Alphamethadol;
- 8 (10) Alpha'-methyl butyryl fentanyl (2-methyl-N-(1-
9 phenethylpiperidin-4-yl)-N-phenylbutanamide);
- 10 ~~[(10)]~~ (11) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-
11 phenyl)ethyl-4-piperidyl]propionanilide; 1-(1-methyl-
12 2-phenylethyl)-4-(N-propanilido)piperidine);
- 13 ~~[(11)]~~ (12) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-
14 thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
- 15 ~~[(12)]~~ (13) Benzethidine;
- 16 ~~[(13)]~~ (14) Benzylfentanyl (N-[1-benzyl-4-piperidyl]-N-
17 phenylpropanamide); its optical isomers, salts, and
18 salts of isomers;
- 19 ~~[(14)]~~ (15) Betacetylmethadol;
- 20 ~~[(15)]~~ (16) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-
21 phenethyl)-4-piperidinyl]-N-phenylpropanamide);



- 1 ~~[(16)]~~ (17) Beta-hydroxy-3-methylfentanyl (N-[1-(2-hydroxy-
2 2-phenethyl)-3-methyl-4-piperidinyl]-N-
3 phenylpropanamide);
- 4 ~~[(17)]~~ (18) Beta-hydroxythiofentanyl (N-[1-[2-hydroxy-2-
5 (thiophen-2-yl)ethyl]piperidin-4-yl]-N-
6 phenylpropionamide);
- 7 ~~[(18)]~~ (19) Betameprodine;
- 8 ~~[(19)]~~ (20) Betamethadol;
- 9 ~~[(20)]~~ (21) Beta-methyl fentanyl (N-phenyl-N-(1-(2-
10 phenylpropyl)piperidin-4-yl)propionamide) (Other name:
11 [beta]-methyl fentanyl);
- 12 ~~[(21)]~~ (22) Beta'-phenyl fentanyl (N-(1-phenethylpiperidin-
13 4-yl)-N,3-diphenylpropanamide) (Other names: [beta]'-
14 phenyl fentanyl; 3-phenylpropanoyl fentanyl);
- 15 ~~[(22)]~~ (23) Betaprodine;
- 16 (24) Brorphine (1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-
17 yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one);
- 18 (25) Butonitazene (2-(2-(4-butoxybenzyl)-5-nitro-1H-
19 benzimidazol-1-yl)-N,N-diethylethan-1-amine);
- 20 ~~[(23)]~~ (26) Butyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-
21 N-phenylbutyramide);



- 1 [~~(24)~~] (27) Clonitazene;
- 2 (28) Crotonyl fentanyl ((E)-N-(1-phenethylpiperidin-4-yl)-
- 3 N-phenylbut-2-enamide);
- 4 (29) Cyclopentyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
- 5 phenylcyclopentanecarboxamide);
- 6 [~~(25)~~] (30) Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-
- 7 yl)-N-phenylcyclopropanecarboxamide);
- 8 [~~(26)~~] (31) Dextromoramide;
- 9 [~~(27)~~] (32) Diampromide;
- 10 [~~(28)~~] (33) Diethylthiambutene;
- 11 [~~(29)~~] (34) Difenoxy;
- 12 [~~(30)~~] (35) Dimenoxadol;
- 13 [~~(31)~~] (36) Dimepheptanol;
- 14 (37) 2',5'-dimethoxyfentanyl (N-(1-(2,5-
- 15 dimethoxyphenethyl)piperidin-4-yl)-N-
- 16 phenylpropionamide);
- 17 [~~(32)~~] (38) Dimethylthiambutene;
- 18 [~~(33)~~] (39) Dioxaphetyl butyrate;
- 19 [~~(34)~~] (40) Dipipanone;
- 20 [~~(35)~~] (41) Ethylmethylthiambutene;



- 1 (42) Etodesnitazene (2-(2-(4-ethoxybenzyl)-1H-benzimidazol-
2 1-yl)-N,N-diethylethan-1-amine) (Other name:
3 etazene);
- 4 [~~+36+~~] (43) Etonitazene;
- 5 [~~+37+~~] (44) Etoxeridine;
- 6 [~~+38+~~] (45) Fentanyl carbamate (ethyl (1-phenethylpiperidin-
7 4-yl) (phenyl) carbamate);
- 8 (46) Flunitazene (N,N-diethyl-2-(2-(4-fluorobenzyl)-5-
9 nitro-1H-benzimidazol-1-yl)ethan-1-amine);
- 10 [~~+39+~~] (47) 4-fluoroisobutyryl fentanyl [N-(4-fluorophenyl)-
11 N-(1-phenethylpiperidin-4-yl)isobutyramide] (Other
12 name: para-fluoroisobutyryl fentanyl);
- 13 [~~+40+~~] (48) 2'-fluoro ortho-fluorofentanyl (N-(1-(2-
14 fluorophenethyl)piperidin-4-yl)-N-(2-
15 fluorophenyl)propionamide) (Other name: 2'-fluoro 2-
16 fluorofentanyl);
- 17 [~~+41+~~] (49) Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-
18 N-phenylfuran-2-carboxamide);
- 19 (50) 3-furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
20 phenylfuran-3-carboxamide);
- 21 [~~+42+~~] (51) Furethidine;



- 1 ~~[(43)]~~ (52) Hydroxypethidine;
- 2 (53) Isobutyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
- 3 phenylisobutyramide);
- 4 (54) Isotonitazene (N,N-diethyl-2-(2-(4-isopropoxybenzyl)-
- 5 5-nitro-1H-benzimidazol-1-yl)ethan-1-amine);
- 6 (55) Isovaleryl fentanyl (3-methyl-N-(1-phenethylpiperidin-
- 7 4-yl)-N-phenylbutanamide);
- 8 ~~[(44)]~~ (56) Ketobemidone;
- 9 ~~[(45)]~~ (57) Levomoramide;
- 10 ~~[(46)]~~ (58) Levophenacymorphan;
- 11 (59) Meta-fluorofentanyl (N-(3-fluorophenyl)-N-(1-
- 12 phenethylpiperidin-4-yl)propionamide);
- 13 (60) Meta-fluoroisobutyryl fentanyl (N-(3-fluorophenyl)-N-
- 14 (1-phenethylpiperidin-4-yl)isobutyramide);
- 15 ~~[(47)]~~ (61) Methoxyacetyl fentanyl (2-methoxy-N-(1-
- 16 phenethylpiperidin-4-yl)-N-phenylacetamide);
- 17 (62) 2-methyl AP-237 (1-(2-methyl-4-(3-phenylprop-2-en-1-
- 18 yl)piperazin-1-yl)butan-1-one);
- 19 ~~[(48)]~~ (63) 4'-methyl acetyl fentanyl (N-(1-(4-
- 20 methylphenethyl)piperidin-4-yl)-N-phenylacetamide);



- 1 ~~(49)~~ (64) 3-methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-
2 4-piperidyl]-N-phenylpropanamide);
- 3 ~~(50)~~ (65) 3-methylthiofentanyl (N-[3-methyl-1-(2-
4 thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
- 5 (66) Metodesnitazene (N,N-diethyl-2-(2-(4-methoxybenzyl)-
6 1H-benzimidazol-1-yl)ethan-1-amine);
- 7 (67) Metonitazene (N,N-diethyl-2-(2-(4-methoxybenzyl)-5-
8 nitro-1H-benzimidazol-1-yl)ethan-1-amine);
- 9 ~~(51)~~ (68) Morpheridine;
- 10 ~~(52)~~ (69) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
- 11 (70) MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine);
- 12 ~~(53)~~ (71) Noracymethadol;
- 13 ~~(54)~~ (72) Norlevorphanol;
- 14 ~~(55)~~ (73) Normethadone;
- 15 ~~(56)~~ (74) Norpipanone;
- 16 (75) N-pyrrolidino etonitazene (2-(4-ethoxybenzyl)-5-nitro-
17 1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole) (Other
18 name: etonitazepyne);
- 19 ~~(57)~~ (76) Ocfentanil [N-(2-fluorophenyl)-2-methoxy-N-(1-
20 phenethylpiperidin-4-yl)acetamide];



- 1 [~~+58+~~] (77) Ortho-fluoroacryl fentanyl (N-(2-fluorophenyl)-
2 N-(1-phenethylpiperidin-4-yl)acrylamide);
- 3 [~~+59+~~] (78) Ortho-fluorobutyryl fentanyl (N-(2-
4 fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide)
5 (Other name: 2-fluorobutyryl fentanyl);
- 6 [~~+60+~~] (79) Ortho-fluorofentanyl (N-(2-fluorophenyl)-N-(1-
7 phenethylpiperidin-4-yl)propionamide) (Other name: 2-
8 fluorofentanyl);
- 9 (80) Ortho-fluorofuranyl fentanyl (N-(2-fluorophenyl)-N-(1-
10 phenethylpiperidin-4-yl)furan-2-carboxamide);
- 11 [~~+61+~~] (81) Ortho-fluoroisobutyryl fentanyl (N-(2-
12 fluorophenyl)-N-(1-phenethylpiperidin-4-
13 yl)isobutyramide);
- 14 [~~+62+~~] (82) Ortho-methyl acetylfentanyl (N-(2-methylphenyl)-
15 N-(1-phenethylpiperidin-4-yl)acetamide) (Other name:
16 2-methyl acetylfentanyl);
- 17 [~~+63+~~] (83) Ortho-methyl methoxyacetyl fentanyl (2-methoxy-
18 N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-
19 yl)acetamide) (Other name: 2-methyl methoxyacetyl
20 fentanyl);



- 1 (84) Para-chloroisobutyryl fentanyl (N-(4-chlorophenyl)-N-
2 (1-phenethylpiperidin-4-yl)isobutyramide);
- 3 [~~+64~~] (85) Para-fluorobutyryl fentanyl (N-(4-fluorophenyl)-
4 N-(1-phenethylpiperidin-4-yl)butyramide);
- 5 [~~+65~~] (86) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-
6 phenethyl)-4-piperidinyl]propanamide[+]);
- 7 [~~+66~~] (87) Para-fluoro furanyl fentanyl (N-(4-
8 fluorophenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-
9 carboxamide);
- 10 (88) Para-methoxybutyryl fentanyl (N-(4-methoxyphenyl)-N-
11 (1-phenethylpiperidin-4-yl)butyramide);
- 12 (89) Para-methoxyfuranyl fentanyl (N-(4-methoxyphenyl)-N-
13 (1-phenethylpiperidin-4-yl)furan-2-carboxamide);
- 14 (90) Para-methylcyclopropyl fentanyl (N-(4-methylphenyl)-N-
15 (1-phenethylpiperidin-4-yl)cyclopropanecarboxamide);
- 16 [~~+67~~] (91) Para-methylfentanyl (N-(4-methylphenyl)-N-(1-
17 phenethylpiperidin-4-yl)propionamide) (Other name: 4-
18 methylfentanyl);
- 19 [~~+68~~] (92) PEPAP (1-(-2-phenethyl)-4-phenyl-4-
20 acetoxypiperidine);
- 21 [~~+69~~] (93) Phenadoxone;



- 1 [~~70~~] (94) Phenampromide;
- 2 [~~71~~] (95) Phenomorphan;
- 3 [~~72~~] (96) Phenoperidine;
- 4 [~~73~~] (97) Phenyl fentanyl (N-(1-phenethylpiperidin-4-yl)-
5 N-phenylbenzamide) (Other name: benzoyl fentanyl);
- 6 [~~74~~] (98) Piritramide;
- 7 [~~75~~] (99) Proheptazine;
- 8 [~~76~~] (100) Properidine;
- 9 [~~77~~] (101) Propiram;
- 10 (102) Protonitazene (N,N-diethyl-2-(5-nitro-2-(4-
11 propoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine);
- 12 [~~78~~] (103) Racemoramide;
- 13 (104) Tetrahydrofuranyl fentanyl (N-(1-phenethylpiperidin-4-
14 yl)-N-phenyltetrahydrofuran-2-carboxamide);
- 15 [~~79~~] (105) Thenylfentanyl (N-[1-(2-thienyl)methyl-4-
16 piperidyl]-N-phenylpropanamide), its optical isomers,
17 salts, and salts of isomers;
- 18 [~~80~~] (106) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-
19 piperidiny]-propanamide);



1 ~~[(81)]~~ (107) Thiofuranyl fentanyl (N-(1-phenethylpiperidin-
2 4-yl)-N-phenylthiophene-2-carboxamide) (Other names:
3 2-thiofuranyl fentanyl; thiophene fentanyl);

4 ~~[(82)]~~ (108) Tilidine;

5 ~~[(83)]~~ (109) Trimeperidine; ~~[and]~~

6 ~~[(84)]~~ (110) U-47700 (3,4-dichloro-N-[2-
7 (dimethylamino)cyclohexyl]-N-methylbenzamide) ~~[+]~~; and
8 (111) Valeryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
9 phenylpentanamide)."

10 2. By amending subsection (d) to read:

11 "(d) Hallucinogenic substances. Unless specifically
12 excepted or unless listed in another schedule, any material,
13 compound, mixture, or preparation that contains any quantity of
14 the following hallucinogenic substances, including their salts,
15 isomers, and salts of isomers, whenever the existence of these
16 salts, isomers, and salts of isomers is possible within the
17 specific chemical designation:

18 (1) Alpha-ethyltryptamine (AET);

19 (2) 2,5-dimethoxy-4-ethylamphetamine (DOET);

20 (3) 2,5-dimethoxyamphetamine (2,5-DMA);

21 (4) 3,4-methylenedioxy amphetamine;



- 1 (5) 3,4-methylenedioxymethamphetamine (MDMA);
- 2 (6) N-hydroxy-3,4-methylenedioxyamphetamine (N-hydroxy-
- 3 MDA);
- 4 (7) 3,4-methylenedioxy-N-ethylamphetamine (MDE);
- 5 (8) 5-methoxy-3,4-methylenedioxy-amphetamine;
- 6 (9) 4-bromo-2,5-dimethoxy-amphetamine (4-bromo-2,5-DMA);
- 7 (10) 4-Bromo-2,5-dimethoxyphenethylamine (Nexus);
- 8 (11) 3,4,5-trimethoxy amphetamine;
- 9 (12) Bufotenine;
- 10 (13) 4-methoxyamphetamine (PMA);
- 11 (14) Diethyltryptamine;
- 12 (15) Dimethyltryptamine;
- 13 (16) 4-methyl-2,5-dimethoxy-amphetamine;
- 14 (17) Gamma hydroxybutyrate (GHB) (some other names include
- 15 gamma hydroxybutyric acid; 4-hydroxybutyrate; 4-
- 16 hydroxybutanoic acid; sodium oxybate; sodium
- 17 oxybutyrate);
- 18 (18) Ibogaine;
- 19 (19) Lysergic acid diethylamide;
- 20 (20) Marijuana;
- 21 (21) Parahexyl;



- 1 (22) Mescaline;
- 2 (23) Peyote;
- 3 (24) N-ethyl-3-piperidyl benzilate;
- 4 (25) N-methyl-3-piperidyl benzilate;
- 5 (26) Psilocybin;
- 6 (27) Psilocyn;
- 7 (28) 1-[1-(2-Thienyl) cyclohexyl] Pyrrolidine (TCPy);
- 8 (29) Ethylamine analog of phencyclidine (PCE);
- 9 (30) Pyrrolidine analog of phencyclidine (PCPy, PHP);
- 10 (31) Thiophene analog of phencyclidine (TPCP; TCP);
- 11 (32) Gamma-butyrolactone, including butyrolactone;
- 12 butyrolactone gamma; 4-butyrolactone; 2(3H)-furanone
- 13 dihydro; dihydro-2(3H)furanone; tetrahydro-2-furanone;
- 14 1,2-butanolide; 1,4-butanolide; 4-butanolide; gamma-
- 15 hydroxybutyric acid lactone; 3-hydroxybutyric acid
- 16 lactone and 4-hydroxybutanoic acid lactone with
- 17 Chemical Abstract Service number 96-48-0 when any such
- 18 substance is intended for human ingestion;
- 19 (33) 1,4 butanediol, including butanediol; butane-1,4-diol;
- 20 1,4- butylenes glycol; butylene glycol; 1,4-
- 21 dihydroxybutane; 1,4- tetramethylene glycol;



- 1 tetramethylene glycol; tetramethylene 1,4- diol with
2 Chemical Abstract Service number 110-63-4 when any
3 such substance is intended for human ingestion;
- 4 (34) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7),
5 its optical isomers, salts, and salts of isomers;
- 6 (35) N-benzylpiperazine (BZP; 1-benzylpiperazine), its
7 optical isomers, salts, and salts of isomers;
- 8 (36) 1-(3-trifluoromethylphenyl)piperazine (TFMPP), its
9 optical isomers, salts, and salts of isomers;
- 10 (37) Alpha-methyltryptamine (AMT);
- 11 (38) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);
- 12 (39) Salvia divinorum;
- 13 (40) Salvinorin A;
- 14 (41) Divinorin A;
- 15 (42) 5-Methoxy-N,N-Dimethyltryptamine [~~(5-MeO-DIPT)~~] (some
16 trade or other names: 5-methoxy-3-[2-
17 (dimethylamino)ethyl]indole; 5-MeO-DMT);
- 18 (43) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);
- 19 (44) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);
- 20 (45) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);
- 21 (46) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);



- 1 (47) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-
2 2);
- 3 (48) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine
4 (2C-T-4);
- 5 (49) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
- 6 (50) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N);
- 7 (51) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);
- 8 (52) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-
9 methoxybenzyl)ethanamine, its optical, positional, and
10 geometric isomers, salts, and salts of isomers (Other
11 names: 25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5);
- 12 (53) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-
13 methoxybenzyl)ethanamine, its optical, positional, and
14 geometric isomers, salts, and salts of isomers (Other
15 names: 25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82);
- 16 (54) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-
17 methoxybenzyl)ethanamine, its optical, positional, and
18 geometric isomers, salts, and salts of isomers (Other
19 names: 25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36);
- 20 (55) N-ethylhexedrone, its optical, positional, and
21 geometric isomers, salts, and salts of isomers (Other



- 1 names: [alpha]-ethylaminohexanophenone; 2-
2 (ethylamino)-1-phenylhexan-1-one);
- 3 (56) Alpha-pyrrolidinohexanophenone, its optical,
4 positional, and geometric isomers, salts, and salts of
5 isomers (Other names: [alpha]-PHP; [alpha]-
6 pyrrolidinohexanophenone; 1-phenyl-2-(pyrrolidin-1-
7 yl)hexan-1-one);
- 8 (57) 4-methyl-alpha-ethylaminopentiophenone, its optical,
9 positional, and geometric isomers, salts, and salts of
10 isomers (Other names: 4-MEAP; 2-(ethylamino)-1-(4-
11 methylphenyl)pentan-1-one);
- 12 (58) 4'-methyl-alpha-pyrrolidinohexiophenone, its optical,
13 positional, and geometric isomers, salts, and salts of
14 isomers (Other names: MPHP; 4'-methyl-alpha-
15 pyrrolidinohexanophenone; 1-(4-methylphenyl)-2-
16 (pyrrolidin-1-yl)hexan-1-one);
- 17 (59) Alpha-pyrrolidinoheptaphenone, its optical,
18 positional, and geometric isomers, salts, and salts of
19 isomers (Other names: PV8; 1-phenyl-2-(pyrrolidin-1-
20 yl)heptan-1-one);



- 1 (60) 4'-chloro-alpha-pyrrolidinovalerophenone, its optical,
2 positional, and geometric isomers, salts, and salts of
3 isomers (Other names: 4-chloro-[alpha]-PVP; 4'-
4 chloro-[alpha]-pyrrolidinopentiophenone; 1-(4-
5 chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one); [and]
6 (61) 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one
7 (methoxetamine, MXE) [\pm];
8 (62) Eutylone (1-(1,3-benzodioxol-5-yl)-2-
9 (ethylamino)butan-1-one) (Other name: bk-EBDB);
10 (63) Zipeprol (1-methoxy-3-[4-(2-methoxy-2-
11 phenylethyl)piperazin-1-yl]-1-phenylpropan-2-ol),
12 including its isomers, esters, ethers, salts, and
13 salts of isomers, esters and ethers, whenever the
14 existence of such isomers, esters, ethers and salts is
15 possible within the specific chemical designation;
16 (64) (1-pentyl-1H-indol-3-yl) (2,2,3,3-
17 tetramethylcyclopropyl)methanone (UR-144);
18 (65) [1-(5-fluoro-pentyl)-1H-indol-3-yl] (2,2,3,3-
19 tetramethylcyclopropyl)methanone (5-fluoro-UR-144,
20 XLR11);



1 (66) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-
2 fluorobenzyl)-1H-indazole-3-carboxamide (Other name:
3 ADB-FUBINACA);

4 (67) Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-
5 carboxamido)-3,3-dimethylbutanoate (Other names:
6 MDMB-CHMICA, MMB-CHMINACA);

7 (68) Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-
8 carboxamido)-3,3-dimethylbutanoate (Other name: MDMB-
9 FUBINACA); and

10 (69) N-ethylpentylone (Other names: ephylone, 1-(1,3-
11 benzodioxol-5-yl)-2-(ethylamino)pentan-1-one)."

12 3. By amending subsection (f) to read:

13 "(f) Stimulants. Unless specifically excepted or unless
14 listed in another schedule, any material, compound, mixture, or
15 preparation that contains any quantity of the following
16 substances having a stimulant effect on the central nervous
17 system, including its salts, isomers, and salts of isomers:

18 (1) Amineptine (7-[(10,11-dihydro-5H-
19 dibenzo[a,d]cyclohepten-5-yl)amino]heptanoic acid);

20 [~~1~~] (2) Aminorex;

21 [~~2~~] (3) Cathinone;



- 1 [~~(3)~~] (4) 4,4'-dimethylaminorex (common name: 4,4'-DMAR);
- 2 (5) Ethylphenidate (ethyl 2-phenyl-2-(piperidin-2-
- 3 yl)acetate);
- 4 [~~(4)~~] (6) Fenethylamine;
- 5 (7) Mesocarb (N-phenyl-N'-(3-(1-phenylpropan-2-yl)-1,2,3-
- 6 oxadiazol-3-ium-5-yl)carbamimidate);
- 7 [~~(5)~~] (8) Methcathinone;
- 8 (9) Methiopropamine (N-methyl-1-(thiophen-2-yl)propan-2-
- 9 amine);
- 10 [~~(6)~~] (10) 4-methylaminorex;
- 11 [~~(7)~~] (11) N-ethylamphetamine;
- 12 [~~(8)~~] (12) N,N-dimethylamphetamine;
- 13 [~~(9)~~] (13) Substituted cathinones, any compound, except
- 14 bupropion or compounds listed under a different
- 15 schedule, structurally derived from 2-aminopropan-1-
- 16 one by substitution at the 1-position with either
- 17 phenyl, naphthyl, or thiophene ring systems, whether
- 18 or not the compound is further modified in any of the
- 19 following ways:
- 20 (A) By substitution in the ring system to any extent
- 21 with alkyl, alkylendioxy, alkoxy, haloalkyl,



1 hydroxyl, or halide substituents, whether or not
2 further substituted in the ring system by one or
3 more other univalent substituents;

4 (B) By substitution at the 3-position with an acyclic
5 alkyl substituent; or

6 (C) By substitution at the 2-amino nitrogen atom with
7 alkyl, dialkyl, benzyl, or methoxybenzyl groups,
8 or by inclusion of the 2-amino nitrogen atom in a
9 cyclic structure.

10 Some other trade names: Mephedrone (2-methylamino-1-p-
11 tolylpropan-1-one), also known as 4-
12 methylmethcathinone (4-MMC), methylephedrone or MMCAT;
13 Methylenedioxypyrovalerone (MDPV, MDPK); methylone or
14 3,4-methylenedioxymethcathinone; and 1-
15 (benzo[d][1,3]dioxol-5-yl)-2-(ethylamino)propan-1-one,
16 monohydrochloride, also known as Ethylone, bk-MDEA
17 hydrochloride, MDEC; 3,4-Methylenedioxy-N-
18 ethylcathinone; bk-Methylenedioxyethylamphetamine, 4-
19 methyl-N-ethylcathinone (4-MEC); 4-methyl-alpha-
20 pyrrolidinopropiophenone (4-MePPP); alpha-
21 pyrrolidinopentiophenone ([alpha]-PVP); 1-(1,3-



1 benzodioxol-5-yl)-2-(methylamino)butan-1-one
2 (butylone, bk-MBDB e); 2-(methylamino)-1-phenylpentan-
3 1-one (pentedrone); 1-(1,3-benzodioxol-5-yl)-2-
4 (methylamino)pentan-1-one (pentylone, bk-MBDP); 4-
5 fluoro-N-methylcathinone (4-FMC, flephedrone); 3-
6 fluoro-N-methylcathinone (3-FMC); 1-(naphthalen-2-yl)-
7 2-(pyrrolidin-1-yl)pentan-1-one (naphyrone); alpha-
8 pyrrolidinobutiophenone ([alpha]-PBP) and their
9 optical, positional, and geometric isomers, salts and
10 salts of isomers, whenever the existence of such
11 salts, isomers, and salts of isomers is possible; and
12 ~~[(10)]~~ (14) 1-(4-methoxyphenyl)-N-methylpropan-2-amine
13 (Other names: para-methoxymethamphetamine; PMMA)."

14 SECTION 2. Section 329-16, Hawaii Revised Statutes, is
15 amended by amending subsection (f) to read as follows:

16 "(f) Immediate precursor. Unless specifically excepted or
17 unless listed in another schedule, any material, compound,
18 mixture, or preparation ~~[which]~~ that contains any quantity of
19 the following substances:

20 (1) Immediate precursor to amphetamine and
21 methamphetamine:

- 1 (A) Phenylacetone, phenyl-2-propanone (P2P), benzyl
2 methyl ketone, methyl benzyl ketone;
- 3 (2) Immediate precursors to phencyclidine (PCP):
- 4 (A) 1-phenylcyclohexylamine; or
- 5 (B) 1-piperidinocyclohexanecarbonitrile (PCC); or
- 6 (3) Immediate precursor to [~~Fentanyl~~] fentanyl:
- 7 (A) [~~4-anilino-N-phenethyl-4-piperidine~~] 4-anilino-N-
8 phenethylpiperidine (ANPP); or
- 9 (B) N-phenyl-N-(piperidin-4-yl)propionamide
10 (norfentanyl)."

11 SECTION 3. Section 329-20, Hawaii Revised Statutes, is
12 amended to read as follows:

13 "**§329-20 Schedule IV.** (a) The controlled substances
14 listed in this section are included in schedule IV.

15 (b) Depressants. Unless specifically excepted or unless
16 listed in another schedule, any material, compound, mixture, or
17 preparation that contains any quantity of the following
18 substances, including its salts, isomers, esters, ethers, and
19 salts of isomers, whenever the existence of these isomers,
20 esters, ethers, and salts is possible within the specific
21 chemical designation, that has a degree of danger or probable



1 danger associated with a depressant effect on the central
2 nervous system:

- 3 (1) Alprazolam;
- 4 (2) Barbital;
- 5 (3) Brexanolone;
- 6 (4) Bromazepam;
- 7 (5) Butorphanol;
- 8 (6) Camazepam;
- 9 (7) Carisoprodol;
- 10 (8) Chloral betaine;
- 11 (9) Chloral hydrate;
- 12 (10) Chlordiazepoxide;
- 13 (11) Clobazam;
- 14 (12) Clonazepam;
- 15 (13) Clorazepate;
- 16 (14) Clotiazepam;
- 17 (15) Cloxazolam;
- 18 (16) Daridorexant;
- 19 (17) Delorazepam;
- 20 (18) Diazepam;
- 21 (19) Dichloralphenazone (Midrin);



- 1 (20) Estazolam;
- 2 (21) Ethchlorvynol;
- 3 (22) Ethinamate;
- 4 (23) Ethyl loflazepate;
- 5 (24) Fludiazepam;
- 6 (25) Flunitrazepam;
- 7 (26) Flurazepam;
- 8 (27) Fospropofol (Lusedra);
- 9 (28) Halazepam;
- 10 (29) Haloxazolam;
- 11 (30) Ketazolam;
- 12 (31) Lemborexant ((1R,2S)-2-[(2,4-dimethylpyrimidin-5-
13 yl)oxymethyl]-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-
14 yl)cyclopropane-1-carboxamide);
- 15 (32) Loprazolam;
- 16 (33) Lorazepam;
- 17 (34) Lormetazepam;
- 18 (35) Mebutamate;
- 19 (36) Medazepam;
- 20 (37) Meprobamate;
- 21 (38) Methohexital;



- 1 (39) Methyphenobarbital (mephobarbital);
- 2 (40) Midazolam;
- 3 (41) Nimetazepam;
- 4 (42) Nitrazepam;
- 5 (43) Nordiazepam;
- 6 (44) Oxazepam;
- 7 (45) Oxazolam;
- 8 (46) Paraldehyde;
- 9 (47) Petrichloral;
- 10 (48) Phenobarbital;
- 11 (49) Pinazepam;
- 12 (50) Prazepam;
- 13 (51) Quazepam;
- 14 (52) Remimazolam;
- 15 (53) Suvorexant;
- 16 (54) Temazepam;
- 17 (55) Tetrazepam;
- 18 (56) Triazolam;
- 19 (57) Zaleplon;
- 20 (58) Zolpidem; [and]
- 21 (59) Zopiclone (Lunesta) [~~+~~]; and



1 (60) Zuranolone.

2 ~~[(c) Fenfluramine. Any material, compound, mixture, or~~
3 ~~preparation which contains any quantity of the following~~
4 ~~substances, including its salts, isomers, and salts of isomers,~~
5 ~~whenever the existence of such salts, isomers, and salts of~~
6 ~~isomers is possible: Fenfluramine.~~

7 ~~(d)]~~ (c) Stimulants. Unless specifically excepted or
8 unless listed in another schedule, any material, compound,
9 mixture, or preparation ~~[which]~~ that contains any quantity of
10 the following substances having a stimulant effect on the
11 central nervous system, including its salts, isomers, and salts
12 of such isomers whenever the existence of such salts, isomers,
13 and salts of isomers is possible within the specific chemical
14 designation:

- 15 (1) Cathine ((+)-norpseudoephedrine);
16 (2) Diethylpropion;
17 (3) Fencamfamin;
18 (4) Fenproporex;
19 (5) Lorcaserin;
20 (6) Mazindol;
21 (7) Mefenorex;



- 1 (8) Modafinil;
- 2 (9) Pemoline (including organometallic complexes and
- 3 chelates thereof);
- 4 (10) Phentermine;
- 5 (11) Pipradrol;
- 6 (12) Serdexmethylphenidate;
- 7 (13) Sibutramine;
- 8 (14) Solriamfetol; and
- 9 (15) SPA (1-dimethylamino-1,2-diphenylethane, lefetamine).

10 ~~[(e)]~~ (d) Other substances. Unless specifically excepted

11 or unless listed in another schedule, any material, compound,

12 mixture, or preparation ~~[which]~~ that contains any quantity of

13 the following substances, including its optical isomers and its

14 salts, isomers, and salts of isomers:

- 15 (1) Pentazocine; and
- 16 (2) Eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl]-
- 17 2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-
- 18 imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic
- 19 acid~~[+]~~]).

20 ~~[(f)]~~ (e) The department of law enforcement may except by

21 rule any compound, mixture, or preparation containing any



1 depressant substance listed in subsection (b) or any stimulant
2 listed in subsection ~~[(d)]~~ (c) from the application of all or
3 any part of this chapter if the compound, mixture, or
4 preparation contains one or more active medicinal ingredients
5 not having a depressant or stimulant effect on the central
6 nervous system, and if the admixtures are included therein in
7 combinations, quantity, proportion, or concentration that
8 vitiate the degree of danger or probable danger of the
9 substances which have a depressant or stimulant effect on the
10 central nervous system.

11 ~~[(g)]~~ (f) Narcotic drugs. Unless specifically excepted or
12 unless listed in another schedule, any material, compound,
13 mixture, or preparation containing any of the following narcotic
14 drugs, or their salts calculated as the free anhydrous base or
15 alkaloid, in limited quantities as set forth below:

16 (1) Not more than one milligram of difenoxin and not less
17 than twenty-five micrograms of atropine sulfate per
18 dosage unit;

19 (2) Dextropropoxyphene [~~(alpha-(+)-4-dimethylamino-1,2-~~
20 ~~diphenyl-3-methyl-2-propionoxybutane)-]~~ (alpha-(+)-4-



1 dimethylamino-1,2-diphenyl-3-methyl-2-
2 propionoxybutane); and
3 (3) 2-[(dimethylamino)methyl]-1-(3-
4 methoxyphenyl)cyclohexanol, its salts, optical and
5 geometric isomers and salts of these isomers
6 (including tramadol)."


7 SECTION 4. Statutory material to be repealed is bracketed
8 and stricken. New statutory material is underscored.

9 SECTION 5. This Act shall take effect on July 1, 2025.



S.B. NO. 1452
S.D. 1
H.D. 2
C.D. 1

APPROVED this 29th day of May, 2025


A handwritten signature in black ink, appearing to read "Jon L. Green". The signature is fluid and cursive, with the first name "Jon" being the most prominent.


GOVERNOR OF THE STATE OF HAWAII

THE SENATE OF THE STATE OF HAWAI‘I

Date: April 30, 2025
Honolulu, Hawai‘i 96813

We hereby certify that the foregoing Bill this day passed Final Reading in the Senate
of the Thirty-Third Legislature of the State of Hawai‘i, Regular Session of 2025.


President of the Senate


Clerk of the Senate

SB No. 1452, SD 1, HD 2, CD 1

THE HOUSE OF REPRESENTATIVES OF THE STATE OF HAWAII

Date: April 30, 2025
Honolulu, Hawaii

We hereby certify that the above-referenced Bill on this day passed Final Reading in the House of Representatives of the Thirty-Third Legislature of the State of Hawaii, Regular Session of 2025.



Nadine K. Nakamura
Speaker
House of Representatives



Brian L. Takeshita
Chief Clerk
House of Representatives